
Opinion|Videos|January 8, 2025
Applying Molecular Testing Results in Treatment Planning
Author(s)Hope S. Rugo, MD
A panelist discusses how molecular testing results, including ESR1 mutations, PIK3CA alterations, and other genomic findings, directly inform treatment decisions and sequencing of therapies for patients with MBC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































